. Author manuscript; available in PMC: 2020 Sep 1.

Published in final edited form as: Am J Obstet Gynecol. 2019 Jun 15;221(3):263.e1–263.e7. doi: 10.1016/j.ajog.2019.06.019

Table 2:

Summary of literature on pharmacokinetic studies of micronized vaginal progesterone in non-pregnant women and this study on pregnant women in the second trimester. AUC: area under curve; Cmax: maximum concentration; Tmax: time to maximum concentration. Data presented as mean±SD or median[IQR]. AUC subscript indicates time over which AUC calculated after one dose.

Study	Study Population	Dose	AUC (ng*h/ml)	Cmax (ng/ml)	Tmax (h)
Paulson 2014⁸	Healthy, premenopausal women (N=9)	200mg micronized vaginal progesterone insert (PVI Ferring Pharmaceutials), rapid disintegrating	138±35 (_0-24)	11.5±3.9	12.0±4.9
Norman 1991¹⁴	Healthy, premenopausal women (N=10)	400mg (Cyclogest suppository, Cox Pharmaceuticals)	308±208(_0-96)	28±18.7	3.1
Erny 1989¹⁹	Healthy, premenopausal women (N=6)	100mg (Utrogestan)	88.8 [49.12-151.7] (_0-24)	8.5 [5.8-12.6]	2.8 [2-4]
Study Number 005323²⁰	Healthy post menopausal women (N=18	100mg (Utrogestan)	209.6±113.7^(_0-96)	6.8±1.6^	9.0±7.1
Archer 1995¹⁵	Healthy post menopausal women (N=10)	100mg (Zetachron)	165.6±76.9(_0-24)	14.5±4.6	3.2±12
Boelig 2018	Healthy pregnant singletons 18-23 weeks’ gestation (N=6)	200mg (Virtus Pharmaceutical)	112 [−43 to 239]^* (_0-24)	11 [2 to 22]^*	12 [4 to 15]

values are change in serum progesterone from baseline.^Converted from original value using 314.46g/mol